OBJECTIVE: The purpose of this study was to investigate the in vitro processing of Cryptococcus neoformans by human alveolar macrophages from HIV-seropositive individuals compared with HIV-seronegative individuals. DESIGN AND METHODS: Bronchalveolar lavage (BAL) was performed on smoking and nonsmoking HIV-seropositive and seronegative volunteers. Lavage cells from the four groups were challenged in vitro with C. neoformans and assessed for fungal binding, phagocytosis, and growth inhibition. RESULTS: The results indicated that BAL cells from the smoking HIV-infected group had increased fungistatic activity compared with HIV-seronegative smokers (mean percentage growth inhibition +/- SD, 77.5 +/- 14.2 versus 59.1 +/- 16.6%; P = 0.015). However, late-staged HIV-infected patients (Centers for Disease Control and Prevention class C3) were found to have decreased fungistasis compared with early stage A patients (63.8 +/- 11.1 versus 83.0 +/- 2.2%; P < 0.05). BAL cells recovered from HIV- seronegative smoking volunteers demonstrated reduced fungistatic activity when compared with BAL cells from HIV- seronegative nonsmokers (56.8 +/- 8.8 versus 83.0 +/- 2.2%; P < 0.001). Smoking also induced a decrease in internalization of C. neoformans by alveolar macrophages as assessed by confocal laser microscopy in both HIV-seronegative and HIV-infected groups. CONCLUSION: We conclude that BAL cells from early stage HIV-1-infected individuals do not have an intrinsic defect in fungistasis of C. neoformans. In fact, it appears that BAL cells from HIV-seropositive people are activated for fungistasis in early HIV infection, although fungistatic activity declines as the disease progresses. Incidentally noted was the finding that smoking decreases the internalization of C. neoformans in both HIV-infected and HIV-seronegative individuals, suggesting the possibility that smoking might enhance the susceptibility to cryptococcosis.
OBJECTIVE: The purpose of this study was to investigate the in vitro processing of Cryptococcus neoformans by human alveolar macrophages from HIV-seropositive individuals compared with HIV-seronegative individuals. DESIGN AND METHODS: Bronchalveolar lavage (BAL) was performed on smoking and nonsmoking HIV-seropositive and seronegative volunteers. Lavage cells from the four groups were challenged in vitro with C. neoformans and assessed for fungal binding, phagocytosis, and growth inhibition. RESULTS: The results indicated that BAL cells from the smoking HIV-infected group had increased fungistatic activity compared with HIV-seronegative smokers (mean percentage growth inhibition +/- SD, 77.5 +/- 14.2 versus 59.1 +/- 16.6%; P = 0.015). However, late-staged HIV-infectedpatients (Centers for Disease Control and Prevention class C3) were found to have decreased fungistasis compared with early stage A patients (63.8 +/- 11.1 versus 83.0 +/- 2.2%; P < 0.05). BAL cells recovered from HIV- seronegative smoking volunteers demonstrated reduced fungistatic activity when compared with BAL cells from HIV- seronegative nonsmokers (56.8 +/- 8.8 versus 83.0 +/- 2.2%; P < 0.001). Smoking also induced a decrease in internalization of C. neoformans by alveolar macrophages as assessed by confocal laser microscopy in both HIV-seronegative and HIV-infected groups. CONCLUSION: We conclude that BAL cells from early stage HIV-1-infected individuals do not have an intrinsic defect in fungistasis of C. neoformans. In fact, it appears that BAL cells from HIV-seropositivepeople are activated for fungistasis in early HIV infection, although fungistatic activity declines as the disease progresses. Incidentally noted was the finding that smoking decreases the internalization of C. neoformans in both HIV-infected and HIV-seronegative individuals, suggesting the possibility that smoking might enhance the susceptibility to cryptococcosis.
Authors: Rafael Van den Bergh; Eric Florence; Erika Vlieghe; Tom Boonefaes; Johan Grooten; Erica Houthuys; Huyen Thi Thanh Tran; Youssef Gali; Patrick De Baetselier; Guido Vanham; Geert Raes Journal: Retrovirology Date: 2010-06-14 Impact factor: 4.602
Authors: Sushma K Cribbs; Jeffrey Lennox; Angela M Caliendo; Lou Ann Brown; David M Guidot Journal: AIDS Res Hum Retroviruses Date: 2015-01 Impact factor: 2.205
Authors: Carter R Coberley; James J Kohler; Joseph N Brown; Joseph T Oshier; Henry V Baker; Michael P Popp; John W Sleasman; Maureen M Goodenow Journal: J Virol Date: 2004-11 Impact factor: 5.103
Authors: Kassandre Leongson; Vincent Cousineau-Côté; Mathieu Goupil; Francine Aumont; Serge Sénéchal; Louis Gaboury; Paul Jolicoeur; James W Kronstad; Louis de Repentigny Journal: Infect Immun Date: 2013-01-22 Impact factor: 3.441
Authors: Björn Corleis; Douglas S Kwon; Abigail E Schiff; Alice H Linder; Shillah N Luhembo; Stephanie Banning; Martin J Deymier; Thomas J Diefenbach; Amy K Dickey; Athe M Tsibris; Alejandro B Balazs; Josalyn L Cho; Benjamin D Medoff; Gerhard Walzl; Robert J Wilkinson; Wendy A Burgers Journal: Sci Rep Date: 2021-02-16 Impact factor: 4.996
Authors: K C Jambo; D H Banda; A M Kankwatira; N Sukumar; T J Allain; R S Heyderman; D G Russell; H C Mwandumba Journal: Mucosal Immunol Date: 2014-01-29 Impact factor: 7.313